As Senior Vice President, Compliance and Project Operations for ADMA Biologics, Ms. Kestenberg is responsible for ensuring Company activities comply with regulations and the expectations of governing bodies as well as oversees company-wide project planning, project management and oversight for clinical programs and operations.

Along with the executive team, Kaitlin was instrumental in conducting due diligence on the Biotest Therapy Business Unit acquisition as well as playing an integral role in integration of corporate operations, compliance and FDA regulated functions. She led significant portions of ADMA’s compliance and quality assurance overhaul, worked on teams developing novel regulatory affairs strategies, led the team responsible for drafting the ASCENIV™ BLA and other significant regulatory submissions and is credited with preparing the company for a successful FDA inspection post acquisition. Ms. Kestenberg has participated in and led numerous FDA interactions for ADMA and has attended multiple face-to-face FDA meetings during her tenure.

Ms. Kestenberg joined ADMA Biologics as Clinical Research Manager in 2011 and has received multiple promotions and positions of increasing responsibility. Prior to joining ADMA, she held roles of increasing responsibility in clinical operations, quality operations and compliance at Acorda Therapeutics and Merck.

Ms. Kestenberg has over 12 years of project management and clinical operations experience including successful phase 3 clinical trials and subsequent regulatory filings. She was responsible for all operational aspects and site management and oversite of ADMA’s Phase III clinical program used as the basis for ADMA’s drug approval for ASCENIV™. She has led cross-functional teams across numerous therapeutic areas including immunology, infectious diseases, multiple sclerosis, congestive heart failure, acute spinal cord injury, HIV, hepatitis Clostridioides difficile, and diabetes.

She holds a bachelor's degree from the State University of New York at Albany and a MSJ from Seton Hall University.

Mr. Chambers joined ADMA Biologics in April 2023 as the Vice President, Quality. He is responsible for ensuring the continued high-performance of ADMA’s Quality Management System, while partnering closely with development, manufacturing, and commercial colleagues to drive a culture of quality excellence and compliance.

Prior to joining ADMA, Mr. Chambers was the Vice President of Global Quality at VBI Vaccines where he led the quality organization during the development and commercial launch of the company’s lead hepatitis B vaccine candidate. Mr. Chambers has 25+ years of experience in the field of quality and has successfully led multiple regulatory inspections both foreign and domestic. His broad background includes quality and operational leadership positions at Merck, Charles River Laboratories, BioReliance, and ElevateBio.

Mr. Chambers holds a BS in Biology from Western Carolina University.

Neal has a talent for building world-class sales teams and leading them to produce consistently stellar results.

In his prior role at Kedrion Biopharma, he held the position of Vice President, Commercial Head for more than 8 years; January 2012 to September 2020 – launching the commercial organization in the United States. He was responsible for hiring and developing the North American commercial organization. The company’s areas of expertise include; Immunology/Neurology, Critical Care, Woman’s Health and Bleeding Disorders. Neal lead the launch or re-launch of 6 biologic products within those specialties. Neal’s success is centered on building a culture based on strong social responsibility. He models his teams around the obligation to the patients they serve, the colleagues they partner with and the communities in which they live.

Neal has spent more than 30 years successfully leading departments and organizations; honing his leadership skills at companies such as United Therapeutics, Novo Nordisk, Wyeth, Genetics Institute and Bristol-Myers Squibb. He has previously served as the Chairman of the Plasma Protein Therapeutics Association (PPTA) North American Advisory Board.

Neal received his Bachelor of Science degree in Pharmacy from the University of Rhode Island and continued his training at Wharton College with courses on strategic leadership, financial business management and team building.

Mr. Daniel Garcia is Vice President of IgG Product Management for ADMA Biologics and is responsible for management of IgG products, serving on strategic business and continuous improvement assignments.  

Mr. Garcia joined ADMA Biologics April of 2016 as the VP of Manufacturing and Technical Operations. Prior to joining ADMA he was Senior Production Manager at Baxter Healthcare, an integral team member developing a new IGIV product. As Senior Director of Operations and Technical Development at Emergent Biosolutions, Mr. Garcia was on the development team and later headed the manufacturing and process development functions in the production of anthrax vaccine (Biothrax), a commercial vaccine for the DOD in support of U.S. Military personnel. At Shanghai RAAS Blood Products, Mr. Garcia led a project as VP of Operations, constructing a 3 million liter automated blood fractionation plant in compliance with U.S. FDA, EMEA and ISO-9001 accreditation standards. Mr. Garcia served as COO at Biocell Laboratories where he was responsible for developing and commercializing numerous FDA approved clinical controls, calibrators and medical devices.  At Molecular GPS, as VP of Manufacturing, Mr. Garcia designed and constructed a cGMP modular cleanroom production facility to manufacture targeted small molecule anti-cancer therapeutics and vaccine.

With over 30 years of Pharmaceutical, Manufacturing, and Operations experience in production of FDA licensed small volume parenteral therapeutics, vaccines and medical devices, Mr. Garcia led development, manufacturing and engineering teams across numerous therapeutic areas. He holds a Bachelor degree from California State University Los Angeles and a Master of Science degree from California State University Northridge.

Mr. Janek joined ADMA Biologics in May of 2021. Prior to joining ADMA, Mr. Janek was a Site Head and integral team member of the Plasma Leadership Team with Takeda. Mr. Janek started his career in 1994 with Alcon Laboratories, an ophthalmic pharmaceutical company in Fort Worth, Texas, and he went on to serve Alcon for twenty years in roles of increasing management responsibility, including the last six years with Alcon as a Site Head in Sao Paulo, Brazil.  Mr. Janek returned to North America in 2014 and held positions of increasing responsibility from Associate Director with Gilead to Site Head with Takeda.

With over 25 years of operations management experience in aseptic formulation, aseptic filling and finishing, including more than 10 years in a Site Head capacity leading manufacturing of globally regulated and licensed pharmaceuticals, biologics (plasma), and medical devices, Mr. Janek has built a strong career in highly technical environments across multiple countries, companies and sites.

Mr. Janek has a proven track record in putting the patient first by improving manufacturing operations, driving regulatory compliance, improving safety, deploying lean and six sigma, assuring business continuity, leading turn-around, developing people and teams, and building and growing cost-competitive organizations.

Mr. Janek is an iTLS Certified Expert and Black Belt in Theory of Constraints, Lean and Six Sigma. He holds a Bachelor degree in Biology from Texas A&M University and a Master of Science degree in Pharmaceutical Manufacturing from Stevens Institute of Technology.

As Vice President, Market Access & National Accounts for ADMA Biologics, Mr. Least brings experience of more than 30 years in the healthcare industry with a focus on specialty product manufacturing, sales, distribution, and commercial operations. Previously as Vice President of Sales for ASD Healthcare, he helped to grow specialty distribution from $9B to over $15B in annual sales. Mr. Least has held various roles and responsibilities including: sales, sales leadership, marketing, medical affairs, training, account management, business development and executive leadership. He has worked for large premier manufacturers and distributors (Searle, Pfizer, Eisai, Johnson & Johnson, AmerisourceBergen), as well as entrepreneurial biotech companies. His extensive knowledge and expertise has resulted in consistent success, with a unique perspective of the U.S. specialty care market and the challenges facing manufacturers, distributors, healthcare providers, health systems and academic medical centers of excellence.

Mr. Pantello is Vice President of Marketing and Corporate Development for ADMA Biologics. He is responsible for leading marketing and business development efforts across all the ADMA immunoglobulin brands.

Prior to joining ADMA Biologics in January of 2018, Mr. Pantello was the account management lead supporting ADMA’s launch preparation activities at H4B Chelsea/Havas Health. At H4B/Havas, he worked hand in hand with the executive team at ADMA Biologics for more than 4 years dissecting the layers of the plasma products market, leading all market research and focus group activities to gain insights and form the basis for the company’s marketing strategies. Drew brings to ADMA the experience of holding various roles of increasing responsibility and working on product launches across a wide range of therapeutic categories for more 20+ years in pharmaceutical market research, advertising and marketing. He has held positions at LM&P, Euro RSCG Life, H4B Chelsea and Havas Health across Account Management and Business Development functions. He was responsible for leading numerous major product launches for brands across immunology, HIV, infectious disease, diabetes and neuroscience.

Mr. Pantello holds a bachelor’s degree in History from Ramapo College of New Jersey.

Mr. Space is the Vice President of Supply Chain and Facility Operations.

He joined ADMA Biologics in September 2018. Prior to this, he worked for Hoffman-La Roche, holding leadership positions in process development, engineering, production, supply chain, finance, IT, and site management. With Roche, he worked on at several sites across the United States and internationally.

Mr. Space has more than 30 years of varied operational experience in the pharmaceutical industry. He led significant capital projects including the design and construction of a $50 million Vitamin plant and a $350 million Greenfield active pharmaceutical ingredient facility. He led a supply chain expansion program for an antiviral targeted at the prevention and treatment of a threatened global influenza pandemic.

Mr. Space holds a master’s in Business Administration from Rutgers University and a bachelor’s degree in Chemical Engineering from the University of Delaware.

As the Vice President, Operations for ADMA BioCenters, Mr. Stremming is responsible for overseeing all aspects of the Plasma Services organization.  This includes driving plasma collections and revenue growth, quality control, and ensuring continued regulatory compliance across all ADMA BioCenters.  Mr. Stremming will work closely with cross-functional teams within both ADMA BioCenters and ADMA Biologics to identify opportunities for process optimization and cost reduction, while building and maintaining relationships with key industry partners and stakeholders.

Mr. Stremming joined ADMA BioCenters in April 2023.  Prior to joining ADMA, Mr. Stremming was the President of Interstate Blood Bank, Inc., President of BPC, & Vice President of the Southeast Plasma Business Unit, within the Grifols Organization.  Mr. Stremming started his career, as a Center Manager, in 2000 with Alpha Therapeutic, a plasma company headquartered in Los Angeles, CA.  Over the past 20 years, Mr. Stremming has been working at Grifols with increasing responsibilities, from Regional Operations Manager, Associate Director of Operations, Director of Program Management, Senior Director of Business Integration (M&A) and cumulating into the role of Vice President of Southeast Plasma Operations.

He holds a bachelor’s degree from Washburn University as well certifications in Lean Six Sigma, Project Management, and Mergers & Acquisitions.

Dr. Wetzstein is the Vice President, Medical Affairs and Scientific Engagement for ADMA Biologics.  In this role, he is responsible to ensure effective and collaborative medical relationships and scientific interchange with ADMA Biologics key medical healthcare partners.  

Gene has a diverse and accomplished career spanning over 20+ years in the academic and institutional practice setting. He earned his BS Pharmaceutical Sciences/ Chemistry and Doctorate of Pharmacy from North Dakota State University.    He then completed a Pharmacy Practice Residency at the University of Utah Hospitals and Clinics and an Oncology/ Hematology/ HSCT Specialty Residency at Moffitt Cancer Center & Research Institute.   He has been Board Certified in Oncology Pharmacy (BCOP) since 2000 and a licensed consultant (FL) pharmacist since 2010.   

Following his specialty residency training, Gene accepted a clinical specialist role in Malignant Hematology / Infectious Disease at Moffitt Cancer Center. Over his 18+ years, he held progressive leadership roles both within the clinical/ research and administrative settings, heading up Clinical Services/ Supportive Care Research and later Chief Pharmacy Officer overseeing the entire pharmacy enterprise. Gene has held multiple national leadership roles including Chair, Pharmacy Leadership Committee of the Alliance of Dedicated Cancers (ADCC).   He has also served on the Board of Directors of the Florida Society of Clinical Oncology (FLASCO).   Gene is recognized throughout the county as a true pharmacy thought leader and has been invited on multiple occasions to speak on oncology/ hematology/ supportive care related topics.   

Prior to joining ADMA Biologics, Gene was at TESARO/ GSK for the last 3 years in customer facing medical roles.    He worked closely with Institutional/ Practice key decision makers in alleviating any potential obstacles or challenges that may arise with the integration of a new product into their Systems/ Formularies.  As Head, US Field Value worked closely with internal partners to develop/ expand clinical data sets, refine, package, and deliver these critical product messages to key institutions/ practices/ centers of excellence.

Dr. Gruenglas is Executive Director, Government Affairs, Health Policy & Scientific Communications, at ADMA Biologics. In this capacity, he works with federal and state stakeholders to develop and advocate for policy that impacts the IVIG therapeutic area, plasma-derived therapies, and biopharmaceuticals. In this role he conducts research in policy, pharmacoeconomics, and ethics. Prior to this he was a Managing Partner and Executive Vice President for several life science consultancies, with a focus on oncology commercialization, health policy, and managed care. Dr. Gruenglas earned his doctorate in health sciences from Massachusetts College of Pharmacy and Health Sciences, where he was elected to Phi Kappa Phi and Alpha Eta honor societies. He holds Masters degrees in bioethics from Harvard Medical School and English Literature from Brooklyn College-CUNY, and a Certificate in Legislative Studies from the Government Affairs Institute at Georgetown University. Dr. Gruenglas is faculty at the College of Arts & Sciences, Boston University, and serves as a volunteer firefighter/EMT in Massachusetts.

Ms. Klostermeyer is the Executive Director, Supply Chain for ADMA Biologics. She is responsible for logistics, inventory control, distribution of finished goods and production scheduling. She develops strategic plans and processes to improve productivity, quality, and efficiency of operations.

Ms. Klostermeyer has over 20 years’ experience in the biologics industry. She has held management positions with increasing responsibility at the ADMA Biologics manufacturing site across, Supply Chain, Accounting and Information Technology.

Ms. Klostermeyer holds a bachelor’s degree in operations management from Florida Atlantic University in Boca Raton, Florida.

Ms. Petersen is the Executive Director, Human Resources for ADMA Biologics. She is responsible for leading the human resources department including talent acquisition, human resources operations, human resources compliance, employee relations as well as benefits and payroll administration.

Ms. Petersen joined ADMA Biologics in October 2022. Prior to joining ADMA, she worked for the last 11 years with Exelon, an energy company, where she held leadership roles in Human Resources with their nuclear generation division and later with distribution and transmission. She has over 25 years of experience with Fortune 100 companies in the field of human resources.

Ms. Petersen holds a bachelor degree in Social Science with a pre-law endorsement along with a Master's in Business Administration (MBA) from Strayer University with a concentration in Human Resources. She has a certificate from the RBL Group in Strategic HR and an Organization Leadership certificate the Institute of Nuclear Power Operations (INPO). She is six sigma certified and applies the foundation of lean principles to all aspects of human resources. She is an active member of the Society of Human Resource Management (SHRM) since 2008.

Mr. Atkinson is the Sr. Director of Operations and has responsibility for the oversight of donor center operational activities.

He joined ADMA Biologics in November 2008 and prior held leadership positions at the American Red Cross and Serologicals. Mr. Atkinson has over 20 years of experience in the Biologics Industry which includes center development, project planning, team building, budget development, compliance activities, and operational improvement initiatives.

Mr. Atkinson received a BS in Business Administration from the University of Maryland.

Mr. Bloom is the Senior Director, Business Development & Corporate Strategy for ADMA Biologics. He serves as a strategic advisor to the senior management team for investor relations and business development opportunities as well as developing messaging for internal and external communications.

Mr. Bloom joined ADMA Biologics in August 2020. Prior to joining ADMA, he held analyst roles at multiple hedge funds including Sphera Global Healthcare and B Group Capital. In his former capacity, Mr. Bloom invested in both private and publicly traded healthcare companies. During his tenure at Sphera, Mr. Bloom played an integral role in growing the investment platform from $500 million assets under management to $1.8 billion at the time of his exit.

He earned his BA in Finance and Accounting from Southern Methodist University.

Mr. Carneiro brings nearly 20 years of Pharmaceutical and Biotechnology experience to ADMA Biologics, beginning his career at Pfizer Pharmaceuticals. Mr. Carneiro was part of a team that launched the newly acquired Anti Infective, Anti-Fungal and Pain Management portfolio to Healthcare Systems and providers as well as alternate sites of care.  He has worked across several therapeutic areas, such as Infectious Disease, Immunology, Neurology and Pain Management, as well as having extensive experience in sales, analytics, marketing, distribution and business development.

Mr. Carneiro’s focus over the past 10 years has been in Market Access and Reimbursement. He was recruited to build out the Market Access function at The Medicines Company, from Cubist Pharmaceuticals and was accountable for developing account specific value-based strategies.  He led a multidisciplinary field-based Market Access team, which was responsible for expanding access for the company’s newly launched portfolio in Nationally and Regionally based Healthcare Systems, Medicare, Medicaid, Commercial Payors, as well as alternate sites of care.  Mr. Carneiro then turned his focus on developing new nationally and regionally based cooperative and specialty pharmacy networks to support the launch of a new oral anti-infective after The Medicines Company Infectious disease franchise was acquired by Melinta Therapeutics.

Mr. Carneiro holds a Bachelor of Science degree in Finance and Economics from Montclair State University and is an active member of the American College of Healthcare Executives (ACHE).

Dr. DeMario is the Senior Director, Scientific & Data Analysis for ADMA Biologics. In this position she is responsible for managing the scientific operations’ discovery and development projects as they relate to the achieving of ADMA’s stated goals.

Dr. DeMario joined ADMA Biologics in 2008 as Director of Quality Systems. In 2017 she moved to Senior Director of ADMA Quality Control Laboratory at the Boca Raton facility before joining Scientific Operations into her current role in 2019.   Previously she held management positions in Quality Control, Manufacturing and Donor Screening at Inhibitex and Immucor. Dr. DeMario has more than 25 years of Quality and Laboratory experience including manufacturing oversight, laboratory management and preparation of regulatory submissions. She has managed teams across numerous plasma protein diagnostic and therapeutic areas for transfusion medicine, and infectious and rare diseases.

She holds a bachelor’s degree from Pfeiffer University, a doctorate from the University of Maryland and performed her post-doctoral studies at the National Cancer Institute.

Mr. Gelberg is the Corporate Controller for ADMA Biologics. Mr. Gelberg is responsible for the financial reporting and accounting operations of ADMA, including preparation of the Company’s consolidated financial statements, SEC reporting, financial planning, and maintaining internal control over financial reporting under the Sarbanes-Oxley Act of 2002.

Mr. Gelberg joined ADMA Biologics in June 2017. Prior to joining ADMA, he held various financial leadership positions at both publicly traded and private companies, including: VeriTeQ Corporation, Fusion Telecommunications, and Cross Match Technologies. He has also worked as an independent consultant advising numerous clients in matters of technical accounting and SEC compliance. Mr. Gelberg began his career in the finance department within the parent corporation of Wyeth, Inc., a global biopharmaceutical company, where he held roles of increasing responsibility for 7 years.

He holds a bachelors’ degree in Economics from the State University of New York at Albany and is a Certified Public Accountant.

Mr. Goldstein is Senior Director, General Counsel, responsible for the oversight of ADMA Biologics’ legal operations. 

He joined ADMA Biologics in April 2021. Prior to this, he worked for DLA Piper LLP (US) for over six years, serving as ADMA Biologics’ external counsel from 2017-2019.  While at DLA Piper, Mr. Goldstein focused his practice on corporate and securities transactions, including venture capital financings, debt and equity financings, private placements and mergers and acquisitions, as well as general corporate law matters and securities law compliance.

Mr. Goldstein holds a B.S. in Finance and Marketing from the University of Maryland and a J.D. from George Washington University.

Mr. Maloney is the Senior Director of Regulatory Affairs for ADMA Biologics. He is responsible for overseeing the development, planning, and implementation of ADMA Regulatory Affairs’ strategic mission as well as ensuring compliance with governmental regulations.

Mr. Maloney joined ADMA Biologics as Senior Director of Regulatory Affairs in September 2017. He worked on the team responsible for all of ADMA’s regulatory interactions post acquisition of the Biotest Therapy Business Unit including the submission of a Prior Approval Supplement for BIVIGAM®, Biologics License Application for ASCENIV™, responses to FDA inspectional observations as well as responding to standard information requests and day to day regulatory interactions and submissions.

Previously, he was as Associate Program Director of Regulatory Affairs at Genentech and was responsible for all US regulatory activities for multiple product lines. Prior to joining Genentech, he held roles of increasing responsibility at several major pharmaceutical companies including Roche, Barr Laboratories, Mylan, and Merck & Company.

Mr. Maloney has more than 20 years of experience in pharmaceuticals and biologics regulatory affairs. His experience spans numerous therapeutic areas including immunology, oncology, endocrinology, dermatology, neurology, and infectious diseases as well as rare diseases.

He holds a bachelor’s degree in Chemistry from Allegheny College.

Mr. Sananes is the Senior Director, Validation for ADMA Biologics. In this position, he is responsible for manufacturing and validation operations.

Mr. Sananes has been at the ADMA Biologics manufacturing site since 1998 in various positions including Manufacturing, Validation, and Process Development.

He has more than 30 years of pharmaceutical experience in plasma and vaccine production. Prior to joining ADMA, Mr. Sananes had roles of increasing responsibility at Roche and Wyeth in both Manufacturing and Quality Control.

Mr. Sananes holds bachelor’s and master’s degrees in Biology and Biochemistry from Rutgers University.

Mr. Sardinas is the Senior Director of Supply Chain Operations for ADMA Biologics. He joined ADMA Biologics in September 2022. Previously, Mr. Sardinas was Senior Director of Operations and Site Leader at HID Global.

Mr. Sardinas began his career with Beckman Coulter and brings over 25 years of experience in the biomedical industry, leading FDA regulated and cGMP manufacturing of instruments and reagents operation sites. As Senior Director of Supply Chain, he led multiple manufacturing sites in North America. He has a proven track record of improving customer satisfaction, assuring business continuity, developing people and teams, and building cost-competitive organizations.

Mr. Sardinas is a Lean and Continuous Process Improvement practitioner, leading and facilitating numerous Kaizens, improving operational productivity, quality, safety, and reducing inventory and product cost.

Mr. Sardinas holds a Master of Business Administration from the Keller School of Management at DeVry University and a Bachelor of Science from Barry University.

Marcin Szutkowski joined ADMA Biologics as Senior Director of Quality Assurance in May of 2021. Prior to joining ADMA, he held various leadership positions including Senior Director of Quality and site Quality Management Representative at Noven Pharmaceuticals, where he oversaw all quality assurance operations, compliance, analytical/process/clinical development quality assurance and quality control. He also served in various roles of increasing responsibility within quality units at Wyeth, Pfizer and Alexion.

Marcin brings 20 years of combined practical experience in quality control, manufacturing quality assurance, quality systems, product release, change management and design assurance within pharmaceutical, vaccine and transdermal systems manufacturing. His experience also includes spearheading a successful compliance remediation program, implementing design controls quality system, and supporting several new product applications and launches.

He holds a Bachelor of Science degree in Chemistry from Hofstra University and a Master of Business Administration from Iona College, Hagan School of Business.